The Discounted Cash Flow (DCF) valuation of Intra-Cellular Therapies Inc (ITCI) is (486.25) USD. With the latest stock price at 131.87 USD, the upside of Intra-Cellular Therapies Inc based on DCF is -468.7%.
Based on the latest price of 131.87 USD and our DCF valuation, Intra-Cellular Therapies Inc (ITCI) is a sell. selling ITCI stocks now will result in a potential gain of 468.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 4.8% - 7.4% | 6.1% |
| Long-term Growth Rate | 3.0% - 4.6% | 3.8% |
| Fair Price | (4,503.82) - (256.07) | (486.25) |
| Upside | -3515.4% - -294.2% | -468.7% |